Cargando…

A phase I, first‐in‐human, randomized dose‐escalation study of anti‐activated factor XII monoclonal antibody garadacimab

Factor XII (FXII) is the principal initiator of the plasma contact system and has proinflammatory and prothrombotic activities. This single‐center, first‐in‐human phase I study aimed to assess the safety and tolerability of single escalating doses of garadacimab, a monoclonal antibody that specifica...

Descripción completa

Detalles Bibliográficos
Autores principales:	McKenzie, Andrew, Roberts, Anthony, Malandkar, Sourabh, Feuersenger, Henrike, Panousis, Con, Pawaskar, Dipti
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932690/ https://www.ncbi.nlm.nih.gov/pubmed/34859955 http://dx.doi.org/10.1111/cts.13180

Ejemplares similares

Pharmacokinetic/pharmacodynamic modeling for dose selection for the first‐in‐human trial of the activated Factor XII inhibitor garadacimab (CSL312)
por: Pawaskar, Dipti, et al.
Publicado: (2021)

HDX-MS study on garadacimab binding to activated FXII reveals potential binding interfaces through differential solvent exposure
por: Ow, Saw Yen, et al.
Publicado: (2023)

Long-term prophylaxis for hereditary angioedema: Initial experiences with garadacimab and lanadelumab
por: Wong, Jane C.Y., et al.
Publicado: (2023)

Efficacy and Safety of Garadacimab in Combination with Standard of Care Treatment in Patients with Severe COVID-19
por: Papi, Alberto, et al.
Publicado: (2023)

Development and Characterization of New Monoclonal Antibodies against Human Recombinant CA XII
por: Dekaminaviciute, Dovile, et al.
Publicado: (2014)

Targeting carbonic anhydrase IX and XII isoforms with small molecule inhibitors and monoclonal antibodies
por: Kciuk, Mateusz, et al.
Publicado: (2022)

First-In-Human, Phase 1, Randomized, Dose-Escalation Trial with Recombinant Anti–IL-20 Monoclonal Antibody in Patients with Psoriasis
por: Gottlieb, Alice B., et al.
Publicado: (2015)

Sifalimumab, a Human Anti–Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study: A Phase I Randomized, Controlled, Dose-Escalation Study
por: Petri, Michelle, et al.
Publicado: (2013)

Inhibitory Monoclonal Antibodies and Their Recombinant Derivatives Targeting Surface-Exposed Carbonic Anhydrase XII on Cancer Cells
por: Stravinskiene, Dovile, et al.
Publicado: (2020)

A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors
por: Becerra, Carlos R., et al.
Publicado: (2014)

Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors
por: Denlinger, Crystal S., et al.
Publicado: (2021)

Monoclonal antibodies to human colon and colorectal carcinoma.
por: Thompson, C. H., et al.
Publicado: (1983)

First studies on tumor associated carbonic anhydrases IX and XII monoclonal antibodies conjugated to small molecule inhibitors
por: Testa, Chiara, et al.
Publicado: (2022)

A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours
por: Lassen, U, et al.
Publicado: (2012)

Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma
por: Boutros, Celine, et al.
Publicado: (2020)

Multiple doses of SHR-1222, a sclerostin monoclonal antibody, in postmenopausal women with osteoporosis: A randomized, double-blind, placebo-controlled, dose-escalation phase 1 trial
por: Dai, Zhijie, et al.
Publicado: (2023)

Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma
por: Fouquet, Guillemette, et al.
Publicado: (2018)

A Randomized Controlled Dose-Escalation Study of LY06006, a Recombinant Humanized Monoclonal Antibody to RANKL, in Chinese Healthy Adults
por: Niu, Suping, et al.
Publicado: (2022)

Phase 1b dose-escalation, safety, and pharmacokinetic study of IC14, a monoclonal antibody against CD14, for the treatment of amyotrophic lateral sclerosis
por: Henderson, Robert D., et al.
Publicado: (2021)

AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors
por: Frentzas, Sophia, et al.
Publicado: (2023)

A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer
por: COHN, ALLEN, et al.
Publicado: (2014)

One-step zero-background IgG reformatting of phage-displayed antibody fragments enabling rapid and high-throughput lead identification
por: Chen, Chao-Guang, et al.
Publicado: (2014)

STUDIES ON ANTIBODY PRODUCTION : XII. INHIBITION OF PRIMING BY DRUGS
por: Butler, William T., et al.
Publicado: (1964)

Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study
por: Goldberg, Avram, et al.
Publicado: (2014)

A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors
por: von Mehren, Margaret, et al.
Publicado: (2014)

A phase Ia dose-escalation trial of Ametumumab (a fully human monoclonal antibody against epidermal growth factor receptor) in patients with advanced solid malignancies
por: Li, Da, et al.
Publicado: (2023)

Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
por: Wheeler, Graham M.
Publicado: (2016)

Fixed Dosing of Monoclonal Antibodies in Oncology
por: Hendrikx, Jeroen J.M.A., et al.
Publicado: (2017)

Assessment and impact of dose escalation on anti-drug antibodies in Fabry disease
por: Lenders, Malte, et al.
Publicado: (2022)

Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study
por: Schiopu, Elena, et al.
Publicado: (2016)

Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors
por: Bauer, Todd M, et al.
Publicado: (2023)

Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
por: Tokuda, Y, et al.
Publicado: (1999)

Single Dose of SHR-1222, a Sclerostin Monoclonal Antibody, in Healthy Men and Postmenopausal Women With Low Bone Mass: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase I Study
por: Dai, Zhijie, et al.
Publicado: (2021)

Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study
por: Zhang, Wen, et al.
Publicado: (2022)

Dose escalation PET imaging for safety and effective therapy dose optimization of a bispecific antibody
por: Wang, Yan, et al.
Publicado: (2020)

A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia
por: Danilov, Alexey V., et al.
Publicado: (2021)

First‐in‐human, randomized, double‐blind, placebo‐controlled, dose escalation trial of the anti‐herpes simplex virus monoclonal antibody HDIT101 in healthy volunteers
por: Blank, Antje, et al.
Publicado: (2022)

Revisiting dose-finding of monoclonal antibodies in migraine
por: Al-Hassany, Linda, et al.
Publicado: (2023)

XII fantasias Gulliver suite /
por: Telemann, Georg Philipp, 1681-1767
Publicado: (1995)

XII fantasias Gulliver suite /
por: Telemann, Georg Philipp, 1681-1767
Publicado: (1995)

Cannot write session to /tmp/vufind_sessions/sess_b7dmc3k6n0pnvgfo4pddsjts56